# A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.

> **NCT03923725** · PHASE3 · COMPLETED · sponsor: **University of Oxford** · enrollment: 2583 (actual)

## Conditions studied

- Plasmodium Falciparum Malaria (Uncomplicated)

## Interventions

- **DRUG:** Artemether-lumefantrine+ Amodiaquine (AL+AQ)
- **DRUG:** Artemether-lumefantrine + placebo (AL+PBO)
- **DRUG:** Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)
- **DRUG:** Artesunate-mefloquine+placebo (AS-MQ+PBO)

## Key facts

- **NCT ID:** NCT03923725
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2024-03-15
- **Final completion:** 2024-03-15
- **Target enrollment:** 2583 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03923725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03923725, "A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03923725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*